Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a post on LinkedIn:
“Patients with advanced or metastatic non–small cell lung cancer (NSCLC) and high PD-L1 expression (≥50%) are commonly treated with PD-(L)1 inhibitor monotherapy, based on the assumption that it offers efficacy comparable to chemo-immunotherapy while avoiding chemotherapy-related toxicity. However, this assumption relies on indirect comparisons, as no head-to-head trials have directly evaluated these strategies in this population. In some countries, such as Italy, regulatory restrictions further limit the use of chemo-immunotherapy in patients with high PD-L1 expression.
In our study, presented at IASLC TTLC, we conducted a comprehensive meta-analysis to address this evidence gap. Using multiple complementary approaches—including trial-level meta-analyses of hazard ratios, meta-regression, network meta-analysis, and reconstructed individual patient data analyses—we consistently observed a significant benefit with chemo-immunotherapy over PD-(L)1 inhibitor monotherapy. This advantage was evident in both progression-free survival and, notably, overall survival.
Take a look at the presentation here for more context and details.”
Other articles featuring Alessandro Di Federico on OncoDaily.